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Abstract 
Objective: Acinetobacter baumanii is a pathogenic bacterium that is the cause of many nosocomial infections. This 
study aimed to determine metallo-β-lactamases (MBL) produced by the A. baumanii isolates obtained from clinical 
samples in Shahrekord, southwest Iran.
Results: A total of 100 A. baumanii were isolated from 250 clinical samples between June 2013 and June 2014. 
Then, the isolates were identified by biochemical tests, and MBL screening was conducted by the phenotypic tests 
modified Hodge, EDTA-disk synergy (EDS), combined disk (CD) and AmpC disc after antibiotic sensitivity test. Using 
PCR technique the bla genes were detected. Eighty-five (85%) isolates were resistant to meropenem and imipenem. 
Phenotypic tests showed that out of the 100 isolates, 46, 59, 50, 65 and 65 isolates were positive: AmpC disk, CD, EDS, 
Modified Hodge and E-test MBL respectively. Gene detection by PCR showed that 23 isolates carried the VIM-1 gene 
and only three isolates carried the IMP-1 gene. The prevalence of metallo-β-lactamases isolates containing A. bau-
manii is increasing. Furthermore, the coexistence of various carbapenemases is dominantly act as a major problem. 
Continuous monitoring of the infections related to these bacteria should be considered to plan an alternative and 
new therapeutic strategies.
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Introduction
Acinetobacter baumanii is recognized for human as a 
pathogenic bacterium that has the potential to acquire 
antibiotic resistance and significant inherent resistance 
in latest years. A. baumanii can survive in distinct cir-
cumstances of the environment. This bacterium is the 
most common pathogen that is responsible for nosoco-
mial infections, including hospital-acquired pneumonia 
and urinary tract, central nervous system, skin, smooth 
tissue, bloodstream, bone, and surgical site infections 
[1]. A. baumanii’s antibiotic resistance is one of the 
reasons why such diseases spread because such bacte-
ria can intrinsically transfer resistance factors to each 
other [2]. Therefore, the treatment of A. baumanii infec-
tions have recently become challenging due to acquisi-
tion of resistance to numerous antibiotics by intrinsic 
and acquired mechanisms [3, 4]. Carbapenems are a 
class of antibiotics that are effective on gram-negative 
and gram-positive bacteria [3, 4]. These pathogens are 
resistant to penicillinases and cephalosporins [5]. The 
main antibiotic resistance mechanism in these classes is 
carbapenemase synthesis [6, 7]. These carbapenems can 
be hydrolyzed by a class of β-lactamases categorized as B 
subclass by Ambler’s classification and known as metallo-
β-lactamases (MBL). MBLs lead to numerous antibiot-
ics resistance including penicillin, cephalosporins and 
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carbapenems [5]. Decreased permeability of the outer 
membrane and increased efflux pump are the other 
mechanisms of carbapenem resistance [8, 9]. There are 
a number of MBLs genes such as imipenemase (IMP), 
Verona integron-encoded metallo-beta-lactamases 
(VIM), Sno Paolo metallo (SPM), New-Delhi metallo-β-
lactamase (NDM), German imipenemase (GIM), Kyorin 
University Hospital imipenemase (KHM), and Australian 
imipenemase (AIM) [10, 11]. IMP, VIM and SPM are the 
most important genes of MBLs that have been detected 
in A. baumanii [12]. It has been suggested that different 
phenotypic tests identify MBLs based on metal-chelat-
ing ability such as EDTA inhibiting MBL activity [13]. 
The phenotypic experiments were used in the present 
research to modify Hodge, double disk synergy (DDS), 
and AmpC disk tests. This research was carried out using 
phenotypic and genotypic methods to identify MBLs 
generated baumanii isolates. All the isolates obtained 
from clinical samples at teaching hospitals in Shahrekord, 
southwest Iran.
Main text
Materials and methods
Patients and sampling
Between June 2013 and May 2014, a total of 250 clini-
cal samples including trachea, blood, urine, wound 
culture, cerebrospinal fluid, and pleural effusion was col-
lected from the inpatients in different wards of Kashani 
and Hajar Hospitals of Shahrekord. This project was 
approved by Shahrekord University of Medical Sciences 
Ethics Committee, and all informed participants comple-
mented a written consent.
Isolation and detection of A. baumanii isolates
A. baumanii strains were isolated and identified by com-
mon chemical tests and techniques [14].
Antimicrobial susceptibility test
Antimicrobial susceptibility test was conducted by Kirby-
Bauer protocol (disk diffusion) using 10 µg imipenem and 
meropenem discs, E-test strips of these antibiotics, and 
MBL strip. Zone inhibition diameters were measured, 
and the results were interpreted with reference to the 
Clinical & Laboratory Standards Institute (CLSI) (CLSI 
2013). Pseudomonas aeruginosa (ATCC ® 2785) was used 
as qualitative control.
Modified Hodge test
A Modified Hodge test was conducted to screen for car-
bapenemase [15, 16]. After suspension culture of Escher-
ichia coli (ATCC 25922), a carbapenem-susceptible 
organism, for 24  h to reach a bacterial turbidity of 0.5 
McFarland standard (NCCLS 2000). The bacteria were 
cultured in the Mueller–Hinton agar using a swab, and 
then the 10 µg meropenem disk was placed in the center 
of the plate. After a 24-h culture, the bacteria did not 
grow around the disc. After a 24-h incubation at 37  °C, 
the existence of inhibition zone was considered positive 
control (Fig. 1).
Fig. 1 Modified Hodge test. Positive strain shows a ‘cloverleaf shaped’ zone of inhibition due to carbapenemase production, while the negative 
strain shows an undistorted zone of inhibition
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EDS and CD tests
EDS test was performed on meropenem- and imipenem-
resistant isolates using meropenem and ceftazidime, and 
CD test to detect MBLs [16, 17]. Practically, a bacterial 
suspension of the 0.5 McFarland standard was cultured 
on the Mueller–Hinton agar, and then two 10 µg carbap-
enem (IMI and MEM) discs as well as a 30 µg ceftazidime 
disc were added to the Mueller–Hinton agar. Subse-
quently, the MBL stop solution (10 µl) was added to the 
culture medium. After a 24-h incubation at 35  °C, the 
inhibition zone diameter was measured and compared 
with other discs. For the EDS test, a bacterial suspension 
of the 0.5 McFarland standard was prepared from the iso-
lates, and the samples were cultured in Mueller–Hinton 
agar. A 10  µg imeropenem disc was placed in the agar 
medium. A blank disc was kept in the inner surface of 
the Mueller–Hinton agar and 10 µl of 0.5 M EDTA was 
added. Likewise, the EDTA disc was transferred to the 
agar surface and kept at 10 mm distance from the mero-
penem or ceftazidime disc. After a 24-h incubation at 
37  °C, the presence of inhibition zone between the two 
discs was considered to represent MBL production.
AmpC disk test
AmpC disk test was conducted to detect MBL in imop-
erem-resistant strains [17–19].
DNA extraction
The DNAs of the bacterial isolates were extracted using a 
DNA extraction kit (Bioneer, Korea, Cat. No. K-3032-2-).
Detection of bla (IMP) and bla (VIM) using PCR
PCR was performed to screen for the VIM and IMP 
genes. Table 1 shows the used primers. PCR consisted of 
forward and reverse primers, DNA pattern, and Master 
Mix. The PCR product was analyzed by polyacrylamide 
gel.
Data analysis
Data including questionnaire data and the results of phe-
notypic and genotypic tests were analyzed by Chi square 
and Fisher’s exact test in the SPSS version 22.
Results
Eighty-five (85%) samples were resistant to meropenem 
and imipenem. 43 number of patients (43%) were female. 
The mean age of the participants was 47.2 years (range; 1 
dy-88 years). The minor and major prevalence of isolated 
bacteria were allocated to the tracheal and abscess sam-
ples respectively.
The tracheal samples carried the most bacteria contain-
ing the MBLs. Fisher’s exact test showed that the associa-
tions between the samples and the presence of bla VIM-1 
(p = 0.28) and bla IMP-1 (p = 0.88) were not statistically 
significant.
Resistance to meropenem and imipenem
After incubation of the plates containing the meropenem 
and imipenem discs and E-test strips, the diameters of 
the inhibition zones were measured and interpreted with 
reference to the CLSI. For the E-test strips, minimum 
inhibitory concentration (MIC) was observed in the areas 
where inhibition zone diameters was increased. E-test 
with (MIC > 32) indicated that 85 samples of the 100 A. 
baumanii isolates were resistant to meropenem and imi-
penem (carbapenem). Based on disk diffusion assay, 81 
samples were resistant and four samples relatively resist-
ant (semi-susceptible).
The results of phenotypic tests for detecting MBLs
46 (46%) cases out of 100 strains were AmpC beta-lacta-
mase producers, and 59 strains positive by CD test, rep-
resenting MBL production. In addition, 50 samples were 
found to be positive in E-test (EDTA disk synergy test). 
Sixty-five samples were found as carbapenemase produc-
ing by the modified Hodge test and 65 as MBL producing 
by E-test.
The results of genotypic tests
After the electrophoresis of PCR products, the bands 
were carefully examined. The presence of the OXA-
51 gene (the specific internal gene of A. baumanii) was 
investigated to confirm the phenotypic tests for A. bau-
manii detection.
Table 1 PCR primers used in this study
Primers Primer sequence Product size References
VIM-1 F
VIM-1 R
TGG TTG TAT ACG TCC CGT CA:F
TGT GTG CTG GAG CAA GTC TA R:
206 bp This study
IMP-1F
IMP-1R
TAA CGG GTG GGG CGT TGT TCCT:F
CGC CCG TGC TGT CGC TAT GAAA R:
bp 179 This study
OXA-51 F
OXA-51 R
TAA TGC TTT GAT CGG CCT TG:F
TGG ATT GCA CTT CAT CTT GG R:
bp 353 Hu et al. [26]
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All samples carried the OXA-51 gene. The presence of 
this gene confirmed the results of biochemical tests for 
A. baumanii detection. The PCR results also showed that 
the A. baumanii isolates from our patients carried the 
VIM-1 and IMP-1 MBL genes. Twenty-three samples 
carried the VIM-1 gene and only three samples had the 
IMP-1 gene (Table 2).
The association between meropenem resistance 
and the presence of bla IMP‑1 and bla VIM‑1 genes 
in Acinetobacter baumanii strains
Chi square test (α = 0.5) showed a significant association 
between meropenem resistance and the presence of bla 
VIM-1 gene in A. baumanii strains (p = 0.22); however, 
there was not relation between meropenem resistance 
and the presence of bla IMP-1 (p = 0.46).
Discussion
A. baumanii, a bacterium with multidrug resistance, is 
considered a highly important pathogen that can endan-
ger human health. This organism is the cause of numer-
ous infections in human, and appearances mainly in 
the people with immunodeficiency or underlying dis-
ease. The infections due to A. baumanii is treated with 
broad-spectrum antibiotics [9]. However, the antibiotic 
resistance of this microorganism has potentially been 
increased, like carbapenem resistance is spreading across 
the world [20]. Carbapenems including imipenem and 
meropenem are drugs of choice for A. baumanii infec-
tion. Recently, the emergence of MBLs (carbapenemase) 
belonging to the classes D and B of beta-lactamases has 
led to the hydrolysis of these drugs, and therefore, A. 
baumanii gain resistance to them [21, 22]. It is highly 
useful to early detection of these genes in carbapenem 
resistant bacteria to control and prevent the spread of 
these bacteria in hospitals. These data can also help the 
physicians to make appropriate prognosis and prescribe 
suitable antibiotic regimens [5]. In this study, we inves-
tigated the prevalence of the most important MBL genes 
that have been identified in A. baumanii strains.
We observed that 85 (85%) isolates were resistant 
to meropenem and imipenem, and the prevalence of 
the IMP-1 and VIM-1 genes were derived 3% and 23% 
respectively.
Nouri et al. [23] studied the prevalence of MBLs in A. 
baumanii in Tehran with the most strains isolated from 
tracheal samples that is similar to our study. So, sterili-
zation of respiratory tubes is one of the most important 
ways to prevent development of this infection in these 
tubes. In our study, the phenotypic tests AmpC disk, CD, 
EDS, modified Hodge, and E-Test MBL showed that 46, 
59, 50, 65, and 65 isolates in order were MBL-producing, 
and only 23 isolates carried the VIM-1 gene and three 
isolates had the IMP-1 gene. This inconsistency in the 
findings can be attributed to the presence of other MBL 
genes or other mechanisms such as defects of porins or 
decreased expression of outer membrane proteins [24].
However, results of phenotypic and genotypic tests 
in several investigations have also consistence with our 
result. For example, Shoja reported that 55% of the iso-
lates were positive by DDS test but did not find any MBL 
producing gene, which is consistent with the studies of 
Manageiro [25] and Hu [26].
Peymani et  al. observed that among 63 carbapenem-
resistant A. baumanii strains, 31 (49%) strains contained 
MBL which 19 (61%) carried bla VIM-1 and the rest had 
bla IMP-1 (31%). These statistics are consistent with our 
study with respect to the prevalence of the VIM-1 gene 
but inconsistent with respect to the prevalence of IMP-1 
that was higher in the study of Peymani et  al. [24]. The 
study of Kouyama et al. [27] indicated that out of the 598 
A. baumanii strains isolated from the patients in the hos-
pitals in different cities of Japan, 4.5% were resistant to 
imipenem and meropenem, which is a lower prevalence 
rate compared to different regions. This can be attrib-
uted to the genetic and climatic conditions in that region 
of the world. A. baumanii resistance rate to imipenem 
and meropenem is heterogeneous in East Asia. It has 
been reported 9.26% in Korea [28], 49% in Taiwan [29], 
50–52.4% in China [30], and 4.5% in Japan, possibly rep-
resenting the effects of geographical differences.
Turner et  al. [31] conducted a large study in Europe 
that showed imipenem resistance rate of A. baumanii 
isolates at the hospital level was 22–26%. Sung et al. [32] 
reported that out of the 31 carbapenem-resistant A. bau-
manii strains, 15 (48.4%) isolates carried the bla IMP-1 
gene, which is comparatively higher than our finding. In 
regard to these statistics, the spread and prevalence of 
both genes are increasing. On the other hand, the lower 
prevalence of bla IMP-1 in the region studied in the cur-
rent study and also the high prevalence and importance 
of bla VIM-1 should be paid special attention.
The coexistence of different carbapenemases is consid-
ered a serious health issue that have remarkable effects 
on alternative and newer therapeutic strategies, stricter 
measures of infection control, and new design for con-
tinuous monitoring. The continuous monitoring of the 
Table 2 The VIM-1 and  IMP-1 genes-producing isolates 
among meropenem- and imipenem-resistant Acinetobacter 
baumanii strains
VIM‑1 IMP‑1 Total
Positive Negative Positive Negative 100
23 (23%) 77 (77%) 3 (3%) 97 (97%)
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prevalence of carbapenem resistance and associated 
mechanisms in A. baumanii strains can help to develop 
appropriate therapeutic strategies against nosocomial 
infections.
Limitations
The lack of investigation on others resistance mecha-
nisms in A. baumanii isolates can be mentioned as one of 
the main limitations of the present study.
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